@wz2013 Avatar @wz2013 GGZ🐌🐌🐌

GGZ🐌🐌🐌 posts on X about $crvs, $ocul, $abvx, $vltlf the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [---] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social category influence stocks 25% finance 7% technology brands 1% celebrities 1% automotive brands 1% countries 1% social networks 1% cryptocurrencies 1%

Social topic influence $crvs #20, $ocul #38, $abvx 9%, $vltlf 9%, whats the 6%, $sofi 6%, guess 4%, $nktr 4%, business 3%, $pcyc 3%

Top accounts mentioned or mentioned by @semodough @pawcio2009 @pharmdca @jayabacus @biovalues @jfais20 @avidresearch @zhaoweiasu @hothomaswphelps @ericjackson @seedy19tron @zipjet @grok @datadinvesting @sofiinsider @tjthewheeldeal @tradingsssss @investorclimber @petermantas @rentyourstocks

Top assets mentioned Ocular Therapeutix, Inc. (OCUL) Abivax SA (ABVX) RAI Finance (SOFI) PepGen Inc. (PEPG) Eli Lilly and Company (LLY) BioAtla, Inc. (BCAB) Arrowhead Research Corporation (ARWR) Palantir Technologies Inc. (PLTR) SpringWorks Therapeutics, Inc. Common Stock (SWTX) UnitedHealth Group (UNH) Vine Coin (VINE) LENZ Therapeutics Inc (LENZ) Tesla, Inc. (TSLA) Viking Therapeutics, Inc (VKTX) Unicycive Therapeutics, Inc. (UNCY) Duolingo, Inc. (DUOL) Molina Healthcare, Inc. (MOH) Kymera Therapeutics, Inc. (KYMR) UiPath, Inc. (PATH) Born in [--] (19)

Top Social Posts

Top posts by engagements in the last [--] hours

"$ocul The market continues to sell into the upcoming readout despite CEOs repeated show of confidence. Reminds me of certain stock which was languishing going into an eventual blockbuster readout. I like my odds here"
X Link 2026-02-13T19:21Z [---] followers, [----] engagements

"Another reference point: Dupixents EASi-75 at 8-week is 36%. Rinvoq is around 65%. The data points I will be watching on Tuesday: [--]. Is there meaningful deepening from 4-week to 8-week. [--]. Is the effect still deepening at the end of 8wk $crvs"
X Link 2026-01-17T17:47Z [---] followers, [----] engagements

"Bro conveniently left out [----] performance. When we are in bull market there are so many option selling posts on my timeline. When we are in a significant drawdown like [----] they all went away. Option selling should only be one of your several strategies. https://t.co/FbtnqrGs30 https://t.co/FbtnqrGs30"
X Link 2026-01-17T21:51Z [---] followers, [---] engagements

"In biotech there are only [--] true clearing events: commercialization and buyout. Most companies will have wrecked finance if they decide to go it alone even when they have a clearly superior product and investors will have many opportunities to pick up shares on cheap"
X Link 2026-01-18T17:27Z [---] followers, [---] engagements

"Buyouts are far and between and may take a long time for anything to materialize. $abvx is a prime example. Stock will get decimated if they go it alone. So now everything is hinged on a BO and that brings out all kinds of rumors and speculation and price gyrates"
X Link 2026-01-18T17:29Z [---] followers, [---] engagements

"Only [--] hours left to vote. $crvs $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%. $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%"
X Link 2026-01-19T15:47Z [---] followers, [---] engagements

"@Investorclimber Very well written. My rough calculation shows there is 8% chance of seeing a renal tox signal in 10mg MAD arm and practically [--] for 5mg. 4% allocation is prudent. $pepg"
X Link 2026-01-29T17:20Z [---] followers, [---] engagements

"@zipjet Given number and cadence are what $ocul expects to see the only failure scenario is that control arm doesnt require rescue and treatment arm requires the same rescue at the same time as they thought control arm would. Probably 5%"
X Link 2026-02-02T22:53Z [---] followers, [---] engagements

"@peter_mantas Take a look at $abvx option call buys since 12/25 and you will change your mind. There are much more degens among us than you think"
X Link 2026-02-04T04:20Z [---] followers, [---] engagements

"@semodough Based on this PR wording 36-wk primary results will be out first and likely the week of 2/16 and then 52-wk secondary results will be out during the conference on 2/25. $ocul"
X Link 2026-02-06T05:11Z [---] followers, [----] engagements

"@RentYourStocks I had a similar experience with $abvx 12/2025 $115 calls. I was short with [--] contracts. Stock closed at $114.94. Wasnt sure if how assignment would go but did get assigned on [--] of them. Monday stock opened at $136.2. Boom the best Xmas gift"
X Link 2026-02-07T17:52Z [---] followers, [---] engagements

"$ocul The transition to Gen [--] formulation has not been discussed enough. Gen2 provides higher bioavailability perfect synchronization with hydrogel degradation and higher initial vitreous concentration. These [--] factors improve the success odds probably by another 20%"
X Link 2026-02-08T19:03Z [---] followers, [----] engagements

"@unemon1 My guess data will be out before 2/24. $pepg"
X Link 2026-02-11T03:57Z [---] followers, [---] engagements

"@money_cruncher Hmm you need to let folks know the consequence of huge drawdown in Roth if high beta names take a dump"
X Link 2026-02-12T03:47Z [---] followers, [---] engagements

"@KevinLMak Love to see you taking significant size on bio names. $nktr $abvx"
X Link 2026-02-12T15:52Z [---] followers, [---] engagements

"$ocul 36-week primary endpoint will be announced on Tuesday. The delta in rescue free rate between active and control arm is : Axpaxli - Control 20% A - C between 20% and 30% A - C 50% A - C between 30% and 50% Axpaxli - Control 20% A - C between 20% and 30% A - C 50% A - C between 30% and 50%"
X Link 2026-02-13T22:26Z [---] followers, [----] engagements

"@pawcio2009 My odds of winning is much much better than that"
X Link 2026-02-13T19:33Z [---] followers, [---] engagements

"The case of $pltr is not that complex. Its a beautiful business with [--] major issues: [--]. Demand on FDEs [--]. Vendor lock-in which some CTOs will never allow. [--]. AI democratization via open-source which will erode their pricing power significantly. $PLTR Had a few days to read through everything Burry has put out on Palantir. First I agree with everything Arny laid out below and it is a must-read around the worst takes of his [-----] word article. I'd like to add the following thoughts: [--]. This feels like a complete and $PLTR Had a few days to read through everything Burry has put out on Palantir."
X Link 2026-02-14T18:04Z [---] followers, [---] engagements

"@pawcio2009 Not my first rodeo. Look past the surface and understand the basis of his confidence: past data trial design gen [--] formulation masked data pattern etc etc. It can absolutely fail but I will take the bet for this setup every time. $ocul"
X Link 2026-02-13T19:30Z [---] followers, [----] engagements

"Who sold $10 Feb calls today must feel really bad now. $ocul @semodough Based on this PR wording 36-wk primary results will be out first and likely the week of 2/16 and then 52-wk secondary results will be out during the conference on 2/25. $ocul @semodough Based on this PR wording 36-wk primary results will be out first and likely the week of 2/16 and then 52-wk secondary results will be out during the conference on 2/25. $ocul"
X Link 2026-02-13T22:39Z [---] followers, [----] engagements

"@semodough 100%. $nktr $crvs will be the leaders in AtD"
X Link 2026-02-14T22:34Z [---] followers, [---] engagements

"@plainyogurt21 @BalaBioResearch @houndcl Well done. I wish you published this way before the announcement tho. The details on the gen2 formulation is spot on. My guess is 80% vs 40%. $ocul"
X Link 2026-02-15T16:46Z [---] followers, [---] engagements

"@pawcio2009 $ocul will seem out of place next week too. lol"
X Link 2026-02-15T16:55Z [---] followers, [---] engagements

"@PersimmonTI Love to buy sub-$40 when a deal is not closed soon. $swtx"
X Link 2025-02-21T01:26Z [---] followers, [---] engagements

"@thexcapitalist What happened to your buy of $unh"
X Link 2025-02-22T21:33Z [---] followers, [----] engagements

"@WhiteCoatMafia In two years $unhs market share at least in the medicare space will shrink by 10%"
X Link 2025-02-22T22:41Z [---] followers, [---] engagements

"@Kross_Roads $amen is failing at AI which will huge implication in the next [--] months"
X Link 2025-07-27T21:42Z [---] followers, [--] engagements

"@grok @Sanctuary_Bio No thats not it since $vine already exploded. is it $lenz"
X Link 2025-07-30T22:22Z [---] followers, [---] engagements

"@RNAiAnalyst Never say never. There will be a first in everything. Will be unconventional and shrewd for $lly to buy $nktr as long as the benefit to $nktr is greater than winning that case"
X Link 2025-10-18T05:29Z [---] followers, [---] engagements

"@Pharmdca No moat. $sofi is eating their lunch"
X Link 2025-11-05T00:27Z [---] followers, [---] engagements

"@DataDInvesting @RJCcapital Right they are still growing on an absolute term but growing more slowly on a relative term. Market punishes a slower growing company. Thats it. Focus on $sofi which is growing faster both in absolute and relative terms"
X Link 2025-11-07T22:16Z [---] followers, [--] engagements

"@ajmotleyfool @Druckenmiller_ No this is a fake account. @standuquesne is the real deal. Have no idea how this account got a blue check. @grok @elonmusk"
X Link 2025-11-10T01:34Z [---] followers, [--] engagements

"@EliteOptions2 @jay2p BYD is the Tesla of China not xpeng"
X Link 2025-11-11T00:03Z [---] followers, [---] engagements

"$nktr. My view is AA will not hit and lly settlement will come out in the same time frame($250M is my guess). Now what will happen to the stock"
X Link 2025-11-23T21:01Z [---] followers, [---] engagements

"@BioValues Yep this is simply good corporate governance. It doesnt mean $BCAB is looking to do reverse split now. Buying opportunity"
X Link 2025-11-24T18:21Z [---] followers, [---] engagements

"@Pharmdca I have been accumulating with $vktx Jan/2027 $30 leaps. This is a no-brainer"
X Link 2025-11-26T16:35Z [---] followers, [----] engagements

"@jfais20 Get back in. $arwr has a long way to go to be fairly valued"
X Link 2025-11-26T22:57Z [---] followers, [---] engagements

"@ilzizzo Yep the rise is significant these last few weeks. $uncy will probably get a PDUFA of 6/26 if they resubmit on time"
X Link 2025-11-30T03:24Z [---] followers, [---] engagements

"@DataDInvesting Without $duol you would have been triple digit though right"
X Link 2025-11-30T16:42Z [---] followers, [---] engagements

"@SoFi_Insider You can do it much better. He got one ticker right(20x). $sofi is your ticket"
X Link 2025-12-04T23:32Z [---] followers, [---] engagements

"@BioValues everyone is waiting for the inflation data tomorrow"
X Link 2025-12-17T19:23Z [---] followers, [--] engagements

"@jayabacus No doubt there is a bidding war going on now. We may see a deal announced by JPM. They are expanding an already large market and $abvx is an easy fix to patent cliff"
X Link 2025-12-20T17:27Z [---] followers, [----] engagements

"@Phoenix3million @jayabacus If BO doesnt happen quickly the price will continue to go up and go up hard as more trials will read out. $abvx"
X Link 2025-12-20T17:54Z [---] followers, [---] engagements

"@Gantosj $vltlf still has a long way up before its fairly valued. [----] will be an inflection point"
X Link 2025-12-22T15:15Z [---] followers, [---] engagements

"@Ashton_1nvests $VLTLF LibertyStream a Lithium producer operating in TX and ND. Lowest raw material cost proven tech TAM 20B. Mass production starts in the next few months. MC is only $130M"
X Link 2025-12-24T17:49Z [---] followers, [---] engagements

"@Pharmdca Top bio is $crvs. Top tech is $VLTLF LibertyStream lithium"
X Link 2025-12-24T19:03Z [---] followers, [----] engagements

"@unusual_whales $VLTLF LibertyStream a DLE Lithium producer operating in TX and ND. Mass production starts in a few months. 100x potential"
X Link 2025-12-26T00:38Z [---] followers, [---] engagements

"@pepemoonboy You might be wise to lay out a few rules for execution and not only go for the weekly or monthly profit. For example only do CSP when stock is above 200MA and pause wheeling when SP500 falls below 200MA etc"
X Link 2025-12-26T18:00Z [---] followers, [---] engagements

"@SoFi_Insider $sofi should trade back up towards Q4 earnings which should be around 1/26. This weakness is a perfect loading opportunity"
X Link 2025-12-31T16:33Z [---] followers, [---] engagements

"@BioValues Im with you on $JSPR. Congrats on $BCAB you traded that one perfectly"
X Link 2025-12-31T18:31Z [---] followers, [---] engagements

"@zipjet Any idea why the recent weakness $ocul"
X Link 2026-01-03T20:11Z [---] followers, [---] engagements

"@SoJustFollowMe @michaeljburry @RayDalio @Citadel @ptj_official Molina is a dying business. $moh"
X Link 2026-01-08T04:54Z [---] followers, [---] engagements

"@avidresearch @semodough Dupi showed placebo-adjusted 35% Easi-75 in P3 (Solo1 and solo2) at week [--] and 46% in P2b. $crvs"
X Link 2026-01-16T22:41Z [---] followers, [---] engagements

"@avidresearch This one is the big one. If we see continuing treatment effect deepening thru [--] weeks it should convince people on the sideline. $crvs"
X Link 2026-01-16T23:22Z [---] followers, [---] engagements

"@jayabacus Welcome to the club $ocul"
X Link 2026-01-16T23:26Z [---] followers, [---] engagements

"@TJTheWheelDeal Why no"
X Link 2026-01-18T03:31Z [---] followers, [---] engagements

"@agamemnus_dev My bad. I should have made it more clear. In clinical trials placebo-adjusted efficacy is the only true efficacy. I just took that for granted"
X Link 2026-01-20T23:43Z [---] followers, [--] engagements

"@zhaoweiasu If SQL passes P3 with flying color with impeccable AE profile as demonstrated so far will you still think it should be behind Dupi $crvs"
X Link 2026-01-21T05:04Z [---] followers, [---] engagements

"@tradingsssss @zhaoweiasu The whole calculus changes if $crvs SQL proves to be curative. This is what Miller and team will try to do in subsequent trials"
X Link 2026-01-21T05:52Z [---] followers, [--] engagements

"@zhaoweiasu @tradingsssss Only risky after $crvs gains another 5x from here. Dont procrastinate and stay on the sideline though"
X Link 2026-01-21T14:44Z [---] followers, [---] engagements

"@spacemnke 100%. Man-made structure is a lot more predicable. He is probably bored the whole climb"
X Link 2026-01-25T19:25Z [---] followers, [--] engagements

"@ConradEnge98050 Very high chance Miller will repeat his success at $pcyc"
X Link 2024-02-18T04:00Z [---] followers, [--] engagements

"@jq1234t Thats a bridge too far. Dr. Miller has been a well-respected researcher and clinician back with a long track record from his IDEC and $PCYC days. This is the first time they released full cohort [--] as well. Here is the previous disclosure on cohort [--] with only [--] patients"
X Link 2025-05-10T17:14Z [---] followers, [---] engagements

"@JoseRestonVA @monaco_biotech Read the S-3 its an amendment to increase the amount declared in a previous S-3 by a mere $11 M. They are not doing an offering now. You should know better. $ixhl"
X Link 2025-07-24T20:26Z [---] followers, [----] engagements

"@HOThomasWPhelps Unfortunately he didnt get much of anything from $pcyc windfall and was forced out early. He will get his fair share on $crvs"
X Link 2025-08-29T17:46Z [---] followers, [---] engagements

"$VLTLF LibertyStream the leader in DLE lithium extraction operates in Delaware Basin(TX) and Williston Basin(ND). They turn waste brine from oil fields into 99% pure Lithium Carbonate which is used by EV battery manufacturing. @ericjackson This is your next 100x. $.7 - $70"
X Link 2025-12-24T17:20Z [---] followers, [---] engagements

"$VLTLF has the lowest raw material cost among all DLE extractors. TAM is $20B. On-site automated refining was successful in Dec [----]. Mass commercial production in [----]. $5 is a mere $1B MC. This is the inflection point where investors should jump in for the rocket ride"
X Link 2025-12-24T17:24Z [---] followers, [---] engagements

"15% up today but still a long way to go 100x. @ericjackson"
X Link 2025-12-26T15:38Z [---] followers, [---] engagements

"RT @HOThomasWPhelps: Analysis of research shows mechanistic convergence between $ABVX #Obefazimod and $CRVS #soquelitinib MOA to have simil"
X Link 2026-01-04T18:05Z [---] followers, [--] engagements

"$abvx $crvs share the same principle in their MOA: modulation vs total blockade on [--] axis. $crvs data will be revealed on 1/12 at JPM. Analysis of research shows mechanistic convergence between $ABVX #Obefazimod and $CRVS #soquelitinib MOA to have similar downstream effects within Th17 cells Obefazimod upregulation of miR-124 and soquelitinib #ITK inhibition both exert regulatory effects on T cell signaling https://t.co/GVyeq10PU7 Analysis of research shows mechanistic convergence between $ABVX #Obefazimod and $CRVS #soquelitinib MOA to have similar downstream effects within Th17 cells"
X Link 2026-01-04T18:07Z [---] followers, [----] engagements

"@ericjackson $VLTLF libertyStream is up 50% YTD. @ericjackson A Canadian gem"
X Link 2026-01-13T20:48Z [---] followers, [---] engagements

"$VLTLF Up 50% in [----] already. A lot more to come"
X Link 2026-01-13T20:49Z [---] followers, [---] engagements

"$VLTLF This is a huge catalyst. Once they become a US company they will be eligible for many grants and opportunities. LibertyStream Calls Special Meeting of Shareholders to Approve Re-Domiciliation to Texas as Part of Its Strategic Pathway Toward a Future U.S. Exchange Listing $LIB.v $VLTLF https://t.co/gnuZ8L9IFd LibertyStream Calls Special Meeting of Shareholders to Approve Re-Domiciliation to Texas as Part of Its Strategic Pathway Toward a Future U.S. Exchange Listing $LIB.v $VLTLF https://t.co/gnuZ8L9IFd"
X Link 2026-01-14T20:20Z [---] followers, [---] engagements

"RT @wz2013: $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID A 40% Between 40% and 50% 60% Between 50% and 60% 40% Between 40% and 50% 60% Between 50% and 60%"
X Link 2026-01-19T15:46Z [---] followers, [--] engagements

"@septdecoeur Understood but I disagree. If $crvs can achieve 60% then that means a 20% improvement over 4-week cohort [--]. Thats blue sky bull case way ahead of Dupi and on par with toxic JAK. If they can achieve 75% thats buyout territory. Someone will take them out before P2"
X Link 2026-01-19T16:32Z [---] followers, [----] engagements

"@pawcio2009 $crvs will be a repeat of $arwr which I was part of as well. Crowded but winning"
X Link 2026-01-20T13:19Z [---] followers, [---] engagements

"@Pharmdca Expect to see $crvs run to $15 and then raise"
X Link 2026-01-20T14:07Z [---] followers, [---] engagements

"@semodough Mind blowing efficacy especially compared to $kymr. $crvs should be worth at least as much"
X Link 2026-01-20T17:02Z [---] followers, [---] engagements

"@pawcio2009 Not just a pop the effect is deepening as the price closed at the high of the day and the entire flow has been turned over. $crvs"
X Link 2026-01-20T21:15Z [---] followers, [---] engagements

"@semodough Last randomization was done around 12/10/2024. Add [--] weeks we get 12/9/2025. Add [--] weeks for database lock cleanse and analysis we get 2/3/2026. Add a week or [--] for holiday slack we will have data between 2/3/2026 and 2/17/2026. $ocul"
X Link 2026-01-24T18:45Z [---] followers, [---] engagements

"@jayabacus @seedy19tron N is much larger than [--] and the cherry picking is actually picking the more difficult patient cohort(including folks who failed SOC). I wish more companies cherry pick like $crvs"
X Link 2026-01-24T18:54Z [---] followers, [---] engagements

"@seedy19tron @HOThomasWPhelps @avidresearch $crvs has a very specific reason for BID as ITK protein has a half-life of [--] hours. Now its strange you keep harping on QD being the entry ticket in I&I oral when this just aint so"
X Link 2026-01-25T01:13Z [---] followers, [---] engagements

"@MarketMovesMatt Dude claims only [--] losing trade in [----] on leveraged ETF but only shows trades starting in Dec At a minimum show all your trades in April. lol"
X Link 2026-01-25T01:28Z [---] followers, [----] engagements

"@TJTheWheelDeal Agree on most. I do think the recent dilutions is the primary reason we are in a slump. Market wants to see how they use those and once it sees accretive effect then we are off to the races again. $sofi"
X Link 2026-01-31T18:05Z [---] followers, [---] engagements

"@MiningFinInd @Tim_Sweeney_TAR Not stupid at all. First I dont think they have share buyback in place. Secondly its not a good look. You have to think about market perception. It will show they have no real thought on how they planned to use the fund in the first place. $sofi"
X Link 2026-01-31T18:11Z [---] followers, [--] engagements

"@zethedeuce @seedy19tron One minor correction: investigators are not from Corvus Corvus is the sponsor. But you are correct $crvs is not involved in the randomization. They can see the data once they come in"
X Link 2026-02-01T19:53Z [---] followers, [---] engagements

"@jakebrowatzke Whats your stop loss on $path"
X Link 2026-02-04T00:20Z [---] followers, [---] engagements

"@Kalshi What else do you expect Jens3n to say lol"
X Link 2026-02-04T20:43Z [---] followers, [--] engagements

"@commonsenseplay @kevinxu But worse than that he didnt go all in. He only bought [----] shares with a $10M account. There is something sinister about lying to your followers on purpose"
X Link 2026-02-06T04:52Z [---] followers, [--] engagements

"$CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%. 40% Between 40% and 50% 60% Between 50% and 60% 40% Between 40% and 50% 60% Between 50% and 60%"
X Link 2026-01-16T21:25Z [---] followers, [----] engagements

"Well only a generalist will ask that question. To biotech investors this is the norm: good data and market doesnt guarantee a good MC. This is a very sector specific phenomenon. @pawcio2009s rule of good data applies. @princetongb The question is if its so good and simple why is it only trading at $115 This isnt a hidden gem biotech story. Everyone in bio knows/likes (or at least doesnt hate) it. If its that well known and liked it usually isnt materially underpriced. Consensus names are @princetongb The question is if its so good and simple why is it only trading at $115 This isnt a hidden"
X Link 2026-01-18T17:24Z [---] followers, [---] engagements

"$abvx Gemini has long told me about the need for $lly to precheck with Bercy on the extent of the regulatory procedure. That precheck will typically take [--] business days. I expect they will get the clarity they need by end of Jan. I expect a formal bid then or shortly after"
X Link 2026-01-19T18:03Z [---] followers, [----] engagements

"Just proves every dog has its day Happens to almost all biotech names. lol Hohns story is wild. In [----] he lost 43% and watched his fund collapse from $19 billion to under $5 billion. Investors fled. He publicly swore off activism after getting humiliated in a railroad proxy fight. [--] years later he just posted the largest single-year hedge fund Hohns story is wild. In [----] he lost 43% and watched his fund collapse from $19 billion to under $5 billion. Investors fled. He publicly swore off activism after getting humiliated in a railroad proxy fight. [--] years later he just posted the largest"
X Link 2026-01-19T18:06Z [---] followers, [---] engagements

"Almost half of you think $crvs hits blue sky bull case Well lets see what happens tomorrow. $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%. $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%"
X Link 2026-01-19T23:58Z [---] followers, [----] engagements

"$crvs Easi-75 75%. And this is achieved in patients failed cortisol and dupi/Jak treatments. Wow blue sky scenario. I dont have enough despite my 150k shares. $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%. $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%"
X Link 2026-01-20T13:08Z [---] followers, [----] engagements

"$crvs Strong price action today. They should raise here for $300M tonight"
X Link 2026-01-20T18:43Z [---] followers, [---] engagements

"28% of voters got it right. Congrats $crvs $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%. $CRVS will release Cohort [--] AtD trial data on Tuesday 1/20 at 8am. Whats the EASI-75 for this 8-week cohort with 200mg BID As reference cohort [--] 200mg BID 4-week showed 50%"
X Link 2026-01-20T20:15Z [---] followers, [---] engagements

"$ocul Did the CFO/COO medical leave news spook the market today"
X Link 2026-01-23T15:40Z [---] followers, [---] engagements

"@semodough Let me guess: $eypt positioned themselves as the honest guy in the room while bashing $ocul as being clever"
X Link 2026-01-23T15:42Z [---] followers, [---] engagements

"@semodough $eypt $ocul Both are down huge today"
X Link 2026-01-23T18:30Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing